Optical imaging predicts tumor response to anti-EGFR therapy

Cancer Biology and Therapy

Volumn 10, Issue 2, 2010, Pages 166-171

  Helman, Emily E ^a   Robert Newman, J ^a   Dean, Nichole R ^a   Zhang, Wenyue ^a   Zinn, Kurt R ^b   Rosenthal, Eben L ^a  

^a Division of Otolaryngology Head and Neck Surgery   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

Cancer therapy; Cetuximab; Fluorescence; Head and neck squamous cell carcinoma; Mouse; Optical imaging; Xenograft

Indexed keywords

CETUXIMAB; DEOXYRIBONUCLEOTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER MODEL; CANCER SIZE; CONTROLLED STUDY; FLUORESCENCE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; INTERNALIZATION; MOUSE; NONHUMAN; PREDICTION; SQUAMOUS CELL CARCINOMA; STEREOMICROSCOPY; TREATMENT RESPONSE; TUMOR XENOGRAFT;

EID: 77955434545     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.10.2.12164     Document Type: Article

References (12)

1. Leon X, Quer M, Orus C, del Prado Venegas M. Can cure be achieved in patients with head and neck carcinomas? The problem of second neoplasm. Expert Rev Anticancer Ther 2001; 1:125-33.
2. Casiglia J, Woo SB. A comprehensive review of oral cancer. Gen Dent 2001; 49:72-82.
3. Perlmutter MA, Johnson JT, Snyderman CH, Cano ER, Myers EN. Functional outcomes after treatment of squamous cell carcinoma of the base of the tongue. Arch Otolaryngol Head Neck Surg 2002; 128:887-91.
4. Gellrich NC, Schimming R, Schramm A, Schmalohr D, Bremerich A, Kugler J. Pain, function and psychologic outcome before, during and after intraoral tumor resection. J Oral Maxillofac Surg 2002; 60:772-7.
5. Blick SK, Scott LJ. Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer. Drugs 2007; 67:2585-607.
6. Dei Tos AP. The biology of epidermal growth factor receptor and its value as a prognostic/predictive factor. Int J Biol Markers 2007; 22:3-9.
7. Bonner JA, De Los Santos J, Waksal HW, Needle MN, Trummel HQ, Raisch KP. Epidermal growth factor receptor as a therapeutic target in head and neck cancer. Semin Radiat Oncol 2002; 12:11-20. (Pubitemid 34920087)
8. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23:1803-10.
9. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354:567-78.
10. Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007; 96:1166-9.
11. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005; 6:279-86.
12. Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics and tumor angiogenesis. Clin Cancer Res 2000; 6:2166-74.